Breast Cancer | Specialty

The OncLive Breast Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of breast cancer, including those that are triple negative, hormone receptor positive, and/or HER2 positive. This page features news articles, interviews in written and video format, and podcasts that focus on treatment advances and ongoing research in breast cancer.

Dr. Anders on Systemic Agents for Patients With Breast Cancer and Brain Mets

November 15th 2016

Carey Anders, MD, assistant professor for the Department of Medicine, Division of Hematology and Oncology, at UNC-Chapel Hill, UNC Linebarger Comprehensive Cancer Center, discusses systemic agents available and in development for patients with breast cancer who also have brain metastases.

Dr. Richard Finn on What's Next for Palbociclib After PALOMA in Breast Cancer

November 11th 2016

Richard Finn, MD associate professor of Medicine at the UCLA David Geffen School of Medicine, discusses what’s next for palbociclib following the PALOMA trials.

PI3K Inhibitors for HR+ Breast Cancer

November 11th 2016

HER2 Mutations in Breast Cancer

November 11th 2016

Biomarkers for CDK4/6 Inhibitors

November 11th 2016

Progression of HR+ Metastatic Breast Cancer

November 11th 2016

HR+ Breast Cancer: FALCON

November 11th 2016

Ongoing Needs in HER2+ Breast Cancer

November 11th 2016

Neratinib in HER2+ Breast Cancer

November 11th 2016

Novel Strategies for HER2+ Metastatic Breast Cancer; Biosimilars

November 11th 2016

Treatment of HER2+ Metastatic Breast Cancer

November 11th 2016

Neoadjuvant T-DM1 in HER2+ Early Breast Cancer

November 11th 2016

Neoadjuvant Lapatinib in HER2+ Early Breast Cancer

November 11th 2016

Neoadjuvant Combinations in HER2+ Breast Cancer

November 11th 2016

HER2-Targeted Therapy in Early Breast Cancer

November 11th 2016

Palbociclib Approved in Europe for HR+/HER2- Breast Cancer

November 10th 2016

The European Commission approved palbociclib (Ibrance) for use in patients with HR-positive, HER2-negative locally advanced or metastatic breast cancer, either in combination with an aromatase inhibitor in the frontline setting or combined with fulvestrant after progression on endocrine therapy.

Dr. Gabriel Hortobagyi on the Impact of MONALEESA-2 Trial in HR+ Breast Cancer

November 9th 2016

Gabriel N. Hortobagyi, MD, professor of Medicine at the University of Texas MD Anderson Cancer Center, discusses the MONALEESA-2 trial, which has shown that the addition of ribociclib to letrozole significantly improved progression-free survival (PFS) in postmenopausal women with hormone receptor (HR)-positive advanced breast cancer.

Dr. Llombart-Cussac on Eribulin in HER2-Negative Metastatic Breast Cancer

November 8th 2016

Antonio Llombart-Cussac, MD, PhD, chairman of the Medical Oncology Service at the University Hospital Arnau de Vilanova in Valencia, Spain, discusses the MERIBEL study, which assessed first-line eribulin (Halaven) for taxane-resistant patients with HER2-negative metastatic breast cancer.

Large Gene Network Required to Predict Response to HER2-Targeted Therapy

November 2nd 2016

Lajos Pusztai, MD, DPhil, discusses findings that suggest it is unlikely that any single gene can predict response to targeted therapy for patients with HER2-positive breast cancer.

Palbociclib Demonstrates Consistent PFS Benefit in ER+ Breast Cancer

November 2nd 2016

Palbociclib demonstrated consistent improvement in progression-free survival when combined with endocrine therapy in patients with advanced estrogen receptor-positive breast cancer.